new cdc guidelines should boost revenue, page-7

Nah, Avexa's product is way too advanced in trial... Biota adds value in the very early stages of development, they would take significant risk trying to run late stage trials themselves or market drugs directly. I would prefer buying a new platform, perhaps even Novogen. DNDN has seen success in trials, that would be another area to look at.